Slide 1: Rising to the Challenges of Rare Disease Treatment
(SOLIGENIX ... Rising to the Challenges of Rare Disease Treatment OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products a
Slide 3: Company Highlights
Company Highlights » Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide © Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) ~ Orphan drug and fast track design
Slide 4: Rare Disease Pipeline
Rare Disease Pipeline BioTherapeutics Product Candidates Preclinical ‘SGx301 [UUUUGRERANEFASTFRACRDESTENATIONSIONM Pr. 3 data 24 2016" Cutaneous T-Cell Lymphoma (CTCL) 6x20 [NUUTOREHAWEFAGTTRNGR DESIGNATIONS Ph. 2 data 24 2017" Pediatric Crohn's Disease"* sax942 [QUUUUUNIFAGTTRACRDESIENTIONNNNNNNINN
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers SGX301 SGX942 Ph. 213 protocol Oral Mucositis 4H: Ph. 3 startin Paediatric Crohn's 2H: FDA clearance | | 4H: Ph. 2/3 start in SGX203* 4H: Ph. 2b startin SGX201* Radiation Enteritis RiVax™* 2H: Ph. 1/2 human safety study start OrbeShield®* * Potential value drivers de
Slide 6: Significant WW Market Potential
Significant WW Market Potential $500+ Assumptions) Oral Mucositis in Head and Neck Cancer ‘90,000 Patients US 190,000 Patients EU 20,000 Patients US 20,000 Patients EU Pediatric Crohn’s Disease 80,000 Patients US 80,000 Patients EU Acute Radiation Enteri Colorectal Cancer 50,000 Patients US 0,000 Pa
Slide 7: Experienced Management and Board of Directors
Experienced Management and Board of Directors Christopher J. ‘Schaber, PhD President & CEO Richard Straube, MD Chief Medical Officer Oreola Donini, PhD Chief Scientific oO Rasappa Arumugham, PhD. VP, Biopharm Development Joseph Warusz, CPA, MBA VP & Acting Chief 26 years of experience Discovery Labo
Slide 8: BioTherapeutics
BioTherapeutics SOLIGENIX :
Slide 9: BioTherapeutics Business Segment
BioTherapeutics Business Segment Commercial targets — unmet medical needs in oncology and inflammation Se Cutaneous T-Cell (Synthetic Hypericin) Lymphoma Oncology and Oncology Supportive Care ‘SGx942 (Dusquetide) Cancer Soligenix $6X201 BioTherapeutics Pena Segment ,21-Dipropionate) Acute Radiation
Slide 10: Cutaneous T-Cell Lymphoma — Disease Overview
Cutaneous T-Cell Lymphoma — Disease Overview Atypical T-cells in dermis Cutaneous T-cell lymphoma (CTCL) Rare class of Non-Hodgkin's Lymphoma (NHL) Malignant T-cells migrate to the skin Cancer forms patches or lesions CTCL affects over 40,000 NHL patients worldwide; currently no cure Two main subtyp
Slide 11: SGX301 — Synthetic Hypericin
SGX301 — Synthetic Hypericin $GX301 is a first-in-class, topical drug applied to CTCL skin lesions followed by activation with safe, visible, fluorescent light to kill malignant T-cells Affects over 40,000 patients annually worldwide No approved front-line therapy for early stage (I-I[A) CTCL (~95%
Slide 12: SGX301 — Phase Response Rate
SGX301 — Phase 2 Response Rate CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy Mi No Summary of CTCL Lesion Responses to Synthetic Hypericin Ointmen! Following Six Weeks of Treatme! fF Responders/Total Percent Responders Hypericin Responders 7/12 58.3% Placebo R
Slide 13: Oral Mucositis — Disease Overview
Oral Mucositis — Disease Overview ~ PA | ret 8 Son 204 > Oral mucositis (OM) Secondary infection © Multi-factorial disease linked to a dysregulation of the innate immune system » OM affects over 180,000 head and neck (H&N) cancer patients worldwide » Debilitating side effect of cancer chemotherapy a
Slide 14: SGX942 — Innate Defense Regulator
SGX942 — Innate Defense Regulator SGX942 (dusquetide) is a first-in-class, injectable drug, called an Innate Defense Regulator (IDR), that modulates the body’s innate immune system to reduce inflammation OM affects over 180,000 H&N cancer patients worldwide No approved drug for OM in H&N cancer; unm
Slide 15: SGX942 — Preliminary Oral Mucositis Results
SGX942 — Preliminary Oral Mucositis Results » Phase 2 exploratory clinical study o Enrolled H&N cancer patients receiving at least 55 Gy radiation and either weekly (30-40mg/m2) or every 3 week (80-100mg/m?) chemotherapy o Dose escalating: Placebo, 1.5, 3.0 and 6.0 mg/kg administered twice weekly o
Slide 16: SGX942 — Preliminary Oral Mucositis Results
SGX942 — Preliminary Oral Mucositis Results » Clinically Meaningful Results © 50% decrease in duration of severe OM overall with 67% decrease in patients receiving aggressive chemotherapy (80-100 mg/m?) = Consistent with decreased incidence and delay in mean onset of severe OM © Increased incidence
Slide 17: Pediatric Crohn's Disease — Disease Overview
Pediatric Crohn’s Disease — Disease Overview Normal mucosa under endoscopy Pediatric Crohn's disease Chronic inflammatory disorder of the gastrointestinal (Gl) tract Diarrhea, rectal bleeding and abdominal pain Resulting in growth failure, malnutrition, pubertal delay and bone demineralization Over
Slide 18: SGX203 — Beclomethasone Dipropionate
SGX203 — Beclomethasone Dipropionate SGX203 is a proprietary oral formulation of immediate and delayed release beclomethasone 17,21-dipropionate (BDP) tablets to treat GI inflammation with less toxicity than the current standard systemic steroid therapy 160,000 children/adolescents with Crohn's dise
Slide 19: Vaccine/BioDefense
Vaccine/BioDefense att Addressing Critical Concerns for Industry and Government SOLIGENIX
Slide 20: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease: HPV and Ebol Vaccines ThermoVax® Vaccine Heat Stabilization Platform BioDefens RiVax™ Ricin Vaccine Soligenix Vaccine / BioDefense Segment" strointestinal Acute Radiation Syndrome * Funded by Government ° (GIARS) Melioidosis (Golireanine
Slide 21: ThermoVax® — Vaccine Thermostability Platform
ThermoVax® — Vaccine Thermostability Platform > ThermoVax® is a proprietary 3 100. freeze-drying process that 5 * 40°C ThermoVax positive results: enables vaccines tobe stored = | \» 40°C Original © Ricin vaccine without refrigeration 2 © Anthrax vaccine E © HPV vaccine Demonstrated retained efficac
Slide 22: RiVax™ — Ricin Toxin Vaccine
RiVax™ — Ricin Toxin Vaccine 100} Heat-stable ricin vaccine provided 7 hades *Late death not rectly 100% protection ina non-human B75 attributed to ricin intoxication primate aerosol challenge model s (right) 5 50. 4@ Vaccine (N=12) g @ Sham (N=6) Demonstrated safety in Phase 1 ” 25 p<0.0001 Studies
Slide 23: OrbeShield® for GI Acute Radiation Syndrome
OrbeShield® for GI Acute Radiation Syndrome Two-tablet BDP system also efficacious in animal models of gastrointestinal acute radiation syndrome (GI ARS) Preliminary proof of concept data in canine model of GI ARS (right) % Survival . = BDP (N=6) © Placebo (N=4) © ° p<0.05 5 10 15 Study Day BARDA Ma
Slide 24: Investment Highlights
Investment Highlights » Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide © Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) ~ Orphan drug and fast track des
Slide 25: Rising to the Challenges of Rare Disease Treatment
ieememerciallenges of Rare Disease Treatment ; NM J www.soligenix.com